Figure 1. (A) Analysis of transitions between the first and second targeted veins and (B) key procedural metrics (n = 621). (C) Sedation subanalysis results (n = 635). (D) Non-GA (n = 167). BMI, body mass index; GA, general anaesthesia; LA, left atrial; LIPV, left inferior pulmonary vein; LSPsAF, long-standing persistent atrial fibrillation; LSPV, left superior pulmonary vein; PAF, paroxysmal atrial fibrillation; PsAF, persistent atrial fibrillation; PV, pulmonary vein; PVI, pulmonary vein isolation; PVI+, pulmonary vein isolation and ablations outside the pulmonary veins; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein. aN is the number of PVs in patients who underwent waiting period and/or adenosine/isoproterenol challenge with available data. n is the number of PVs with reconnection observed in ≥1 PV. bN is the number of patients who underwent waiting period and/or adenosine/isoproterenol challenge with available data. n is the number of patients with reconnection observed in ≥1 PV. The figure is courtesy of Biosense Webster, Inc., part of Johnson & Johnson MedTech. ©All rights reserved.